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ABSTRACT: A novel transdermal hyaluronic acid (HA) conjugated with bovine serum albumin (BSA) was developed in the
form of solid-in-oil (S/O) nanodispersion (129.7 nm mean diameter). Ex vivo skin penetration analysis by ﬂuorescence and
confocal observation of histological skin sections revealed the ability of BSA/HA nanodispersions to cross the stratum corneum
and penetrate into the dermis. Furthermore, no signiﬁcant toxicity was found in ﬁbroblast and keratinocyte cells in vitro. These
results proved the potential of the developed nanodispersion for transdermal delivery of hyaluronic acid constituting a high value
to biopharmaceutical and cosmetics industries.
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1. INTRODUCTION
Skin is the largest organ in the body, with the major function of
protecting from dehydration and unwanted eﬀects caused by the
external environment.1 Aging is a dynamic process that may
result from repeated chemical assault (e.g., soaps or cosmetics)
or from a lifetime of exposure to UV radiation from sunlight.2
The presence of hyaluronic acid (HA) in pharmaceutical−
cosmetic formulations would be able to protect the skin against
these side eﬀects.3 It is well-known that HA can reduce facial lines
and wrinkles in the long term with fewer side eﬀects and better
tolerability compared with the use of collagen.4−6 HA is present
in the intercellular matrix of most vertebrate connective tissues,
especially skin, where it has a protective, structure stabilizing, and
shock-absorbing role.7 HA is a naturally occurring biopolymer,
polyanionic polysaccharide that consists of β-glucoronic acid and
N-acetyl-D-glucosamine with hydrophilic properties (a very high
aﬃnity for attracting and binding water molecules).8 Its
molecular weight is strongly dependent on its source of
commercial production9 and varies between 102 and 104 kDa
in diﬀerent tissues and ﬂuids.10
Properties of HA including speciﬁc biocompatibility, non-
immunogenicity, biodegradability, viscoelasticity, hydration, and
lubrication11,12 make this polysaccharide potentially useful in
food, medical, pharmaceutical, and cosmetic industries.
HA controls tissue hydration and exists in hydrated networks
with collagen ﬁbers in the intercellular matrix. It also constitutes
the backbone of cartilage proteoglycan. Because of its unique
physicochemical properties and various biological functions, HA
and modiﬁed HA have been extensively investigated and widely
used for pharmaceutical and medical applications, namely, as a
novel drug carrier for target speciﬁc and long-acting delivery of
proteins, peptides, and nucleotide therapeutics.13 In contrast,
cosmetic and food applications have received little attention.14
Hydrophilic macromolecules, like HA, constitute a challenging
issue in the development of transdermal transport systems to
cross the intact skin and reach the lipid bilayers.15,16 Transdermal
transport systems have many advantages over other systems
because they can promote eﬀective patient compliance without
painful injections.17,18 Despite these beneﬁts, the low bioavailability
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constitutes the major disadvantage of transdermal transport
systems due to poor skin permeability. This is mainly due to the
stratum corneum, the outermost layer of skin, which forms a barrier
based on epidermal lipids. This fact allows transport of compounds
only with low molecular weight (Mw) (<500 Da).
19−21 The barrier
permeability provided evidence for the crucial nature of the three
major lipid species: cholesterol, ceramides, and free fatty acids.22,23
Thus, as the decisive role of skin care, strategies focus on restoring,
repairing, or protecting the barrier skin by application of selected
lipids for improving skin function and appearance.24 To circumvent
the limitation of transporting hydrophilic macromolecules across the
skin layers, a S/O dispersion technology was designed assuming the
formation of an external layer of a hydrophobic moiety.15 This
technology was developed as a novel platform for oral and skin drug
delivery systems.25
In our previous study, a large protein, BSA (66 kDa), was
coated with hydrophobic surfactant molecules using an adapted
and optimized S/O methodology.26 A formulation containing
small dispersions (160 nm mean diameter) that successfully
cross the skin barriers was achieved.26
The major delivery method for biopharmaceutics to human
body is currently done via subcutaneous or intravenous
administration, in particular for rejuvenative medicine as a ﬁller
for cutaneous lines and wrinkles.27,28 The potential of HA for
transdermal delivery has been reported as a promising drug
carrier.13,14,29 There is no pharmaceutical/cosmetic formulation
study available using HA in the form of S/O nanodispersion
exhibiting a good permeability through all skin layers. Herein,
transdermal capacity and bioavailability of BSA/HA solid-in-oil
nanodispersions with diﬀerent molecular weight HA were
investigated. In vitro permeation proﬁle into pig skin was studied
quantitatively and qualitatively.
2. EXPERIMENTAL SECTION
2.1. Materials. BSA-FITC, chloroform, and isopropyl
myristate were commercially supplied by Sigma-Aldrich and
used as received. Sucrose ester (SE), Sisterna SP10-C, was
purchased from Sisterna (Sisterna, The Netherlands). Hyalur-
onic acid of molecular weight (Mw) 800 kDa from cocks comb
was supplied by Sigma Aldrich. Hyaluronic acid (50 and 15 kDa)
was kindly provided by Lifecore (Lifecore, USA) and (HA 100≤
Mw ≤ 300 and 20 ≤ Mw ≤ 50 kDa) from Soliance (Soliance,
France), both from bacterial source. The products used for
histology procedure were supplied by Fisher Healthcare (U.K.).
The transdermal studies were performed using pig skin from a
slaughterhouse and kindly supplied by Matadouro Central de
Entre Douro e Minho (Portugal). For histology studies the
Cryoprotectant Tissue-Tek Oct compound was purchased from
Sakura (The Netherlands) and the Thermo Scientiﬁc Shandon
Immu-Mount was purchased from Fisher Healthcare (U.K.). All
other reagents were laboratory grade without any further
puriﬁcation.
2.2. Preparation of S/O BSANanodispersions Containing
Hyaluronic Acid. The S/O protein/polymer (BSA-FITC/HA)
nanodispersions were prepared by an adaptation of our previous
method.26 Brieﬂy, the initial complex between sucrose ester (SE)
surfactant and protein (mixed with hyaluronic acid) was formed
by high pressure homogenization at 1000 bar (EmulsiFlex-C3,
Avestin, Canada). For this, the concentrations of BSA-FITC used
were 0.1, 0.25, 0.5, and 1 mg/mL, mixed with several amounts of
hyaluronic acid, namely, 0.003, 0.006, and 0.009 mg/mL, for the
diﬀerent HA molecular weights tested. For each formulation a
ﬁxed amount, 25 mg/mL, of SE surfactant (SP10-C) was applied.
Then a lyophilization step was performed aiming to eliminate
water and chloroform (solvent used for surfactant solubilization)
attaining a solid surfactant−protein complex. This complex was
dispersed in oil, isopropyl myristate (IPM), by ultrasonication
using an ultrasound probe (20 kHz Sonics & Materials Vibracell
CV33) ﬁtted with a 3 mm diameter titanium microtip, forming
the ﬁnal S/O nanodispersion.
2.3. S/O Nanodispersion Characterization. 2.3.1. Deter-
mination of Production Yield. The nanodispersion production
yield was determined by centrifugation (15000g, 30 min) and
separation of the formulated part from the aqueous preparation
medium containing the nonformulated protein. The amount of
free BSA-FITC was determined in the supernatant by the Lowry
method protein assay (Sigma), measuring the absorbance by
spectrophotometry (Microplate Reader Synergy MX, Bioteck
Instruments) at 750 nm.30 Each sample was assayed in triplicate
(n = 3). The concentration of protein was determined by a
calibration curve. The S/O nanodispersion production yield








2.3.2. Assembly Eﬃciency of Hyaluronic Acid. Assembly
eﬃciency (AE) of hyaluronic acid in BSA-FITC solid-in-oil
nanodispersions was determined by their separation from the
aqueous preparation medium containing the free hyaluronic acid
by centrifugation (2000g, 30 min) using Centricon tubes
(molecular weight cutoﬀ 1000 kDa). The amount of free
hyaluronic acid was determined in the supernatant by UV
spectrophotometry, using Microplate Reader Synergy MX
(Bioteck Instruments) at 185 nm.




[HA]i is the initial concentration of hyaluronic acid used, and
[HA]f is the ﬁnal concentration of hyaluronic acid in supernatant.
2.3.3. Determination of z-Average Diameter. The z-average
diameter of nanodispersions was determined at 25± 0.1 °Cusing
a Malvern Zetasizer NS (Malvern Instruments) by photon
correlation spectroscopy (PCS). For each nanodispersion formula-
tion the average diameter was measured in triplicate.
2.3.4. S/O Nanodispersion Morphology: Transmission
ElectronMicroscopy (TEM).Themorphological characterization
of nanodispersions was conducted using transmission electron
microscopy technique in an electron microscope model LEICA
S360 with a backscattered and secondary electron detector, at
50000×magniﬁcation. The samples were placed on copper grids
with carbon ﬁlm for TEM observation.
2.3.5. S/O Nanodispersion Stability. The physicochemical
stability of nanodispersions was assessed taking into account
their storage stability. The stability was evaluated by size
distribution and polydispersity index (PDI). The formulations
were stored at room temperature over 3 months.
The biological stability of nanodispersions by oxidative
evaluation was also performed. For that, the lipid peroxidation
experimental protocol was used. The detection of lipid
peroxidation was assessed using a spectrophotometrical
technique to measure one of the secondary products formed
and used to estimate lipid peroxidation, the malondialdehyde
(MDA), after the reaction with thiobarbituric acid.31
2.4. In Vitro Permeation Studies through Pig Skin.
Ex vivo study of permeation through full thickness pig skin was
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achieved using the horizontal Franz diﬀusion cell (V-Series
Stirrers for Franz Cells) (PermeGear, USA).26 The pig skin
specimens were provided by a local slaughterhouse. First, the
skin was removed from the pig without any steam cleaning.
Then, the subcutaneous fat was maximally removed and was cut
to an appropriate size and immediately mounted in the Franz
diﬀusion cell, with the SC side facing the donor compartment.
The receptor compartment was ﬁlled with 5 mL of PBS solution
(phosphate buﬀered saline 0.01 M, pH 7.4), which was
continuously stirred with a small magnetic bar and thermostated
at 37 ± 1 °C throughout the experiments to reach the
physiological skin temperature (i.e., 32 ± 1 °C). The amount
of the S/O nanodispersion applied to the skin surface was
approximately 300 μL. At regular intervals of 0, 2, 4, 6, 8, 24, 48,
and 72 h, samples of the receiving solution were collected. Each
sample removed was replaced with fresh buﬀer. To evaluate the
transdermal permeation of S/O nanodispersion, the protein
concentration was quantiﬁed using the Lowry assay on the
supernatant on each sample removed in the predetermined
intervals. For the detection of HA, concentration was performed
by monitoring the UV absorbance at 185 nm. Controls were
performed for all time points without protein and HA.
2.4.1. Fluorescence and Confocal Microscopy Studies. In
order to evaluate the penetration of nanodispersions through the
skin, ﬂuorescent and confocal laser scanning microscopy was
performed after 72 h, the total time of the in vitro penetration
experiment. For imaging purposes, BSA and HA were labeled
with FITC (ﬂuorescein isocyanate) and RITC (Rhodamine
isocyanate), respectively. Skin samples were visualized by
ﬂuorescence microscopy taking into account diﬀerent ap-
proaches to generate a phase contrast and diﬀerential
interference contrast microscopy analysis. These two contrasting
optical microscopy methods give very diﬀerent but comple-
mentary data. Additionally, skin samples were optically scanned
at diﬀerent increments through the Z-axis of a confocal laser
microscope (Zeiss LSM 510). The image reconstructions were
made using “Imaris” image analysis software.
2.5. Cytotoxicity Evaluation.The nanodispersions of BSA/
HA were evaluated by one of the mostly used cytotoxicity or cell
proliferation assays, the MTT, which is a quantitative colorimetric
assay. In this assay, the yellow tetrazolium salt MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) is re-
duced by living cells to blue formazan crystals, which must be
solubilized in a solvent, such as isopropanol.32 The MTT assay
appeared to be a sensitive test which shows linearity over a broad
range of cell densities.32,33
The BJ5ta cell line (normal human skin ﬁbroblasts) was
maintained according to ATCC recommendations (4 parts
Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 1 part of
Medium 199, 10% (v/v) of fetal bovine serum (FBS), 1% (v/v)
of penicillin/streptomycin solution, and 0.01 mg/mL hygrom-
ycin B). The cells were maintained at 37 °C in a humidiﬁed
atmosphere of 5% CO2. Culture medium was refreshed every
2−3 days. Cells were seeded at a density of 80000 cells/well on
24-well tissue culture polystyrene plates (TPP, Switzerland), on
the day before experiments, and then exposed to diﬀerent
nanodispersion formulation concentrations in a ﬁnal volume of
0.5 mL. Several controls were performed simultaneously: the
death control with 15% (v/v) dimethyl sulfoxide (DMSO), the
100% viability control with just fresh medium, and a maximum
dilution control with 50% (v/v) phosphate buﬀered saline (PBS)
to evaluate the eﬀect of medium dilution. At 24 and 48 h of
exposure, cell viability was determined using the MTT
assay.34−37
The human keratinocyte cell line NCTC 2544 was cultured in
DMEM supplemented with 7% (v/v) FBS and 1% (v/v) of
penicillin/streptomycin solution. Culture medium was refreshed
every 2−3 days. Cells were seeded at a density of 45000 cells/well
on 24-well tissue culture polystyrene plates (TPP, Switzerland),
the day before experiments. The subsequent procedure was the
same as that described for the BJ5ta line.
The cytotoxicity was evaluated by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In the MTT
reduction assay the medium containing diﬀerent dilutions of the
Figure 1. Schematic overview of the preparation method of S/O BSA/HA nanodispersions.
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nanodispersion formulation was removed, the wells were washed
with warm PBS, and 0.5 mL of 0.5 mg/mL MTT solution was
added to each well. After incubation for 2 h at 37 °C, the medium
was removed and the formazan crystals were solubilized in 0.5 mL
of DMSO/ethanol solution. The plate was shaken for 5 min on a
plate shaker, and the absorbance was measured at 570 nm in a
microplate reader (Spectramax 340PC, Molecular Devices,
Sunnyvale, CA, U.S.A.). The absorbance is directly proportional
to the number of viable cells. The procedure was performed at least
three times with duplicates, and the average values are presented.
2.6. Statistical Analysis. Statistical analysis of the
experimental results was performed using analysis of variance
(ANOVA). Diﬀerences were considered statistically signiﬁcant at
p < 0.05. All data values are represented as mean ± standard
deviation of at least 3 measurements.
3. RESULTS
3.1. Preparation and Characterization of S/O Nano-
dispersions of BSA/HA. The S/O nanodispersion containing
the conjugate BSA/HA was obtained by coating the BSA/HA
Figure 2. Evaluation of z-average (nm) and PDI (mean ± SD, n = 3) of S/O nanodispersions varying the amount of BSA mixed with several
concentrations of diﬀerent molecular weight of HA. Optimal particle characteristics in terms of size are lower than 200 nm and PDI lower than 0.280.
Their composition corresponds to 0.5 mg/mL of BSA with 0.006 mg/mL of HA for diﬀerent molecular weight of HA; and for BSA formulation without
HA, 1 mg/mL.
Figure 3. Stability of produced nanodispersions over time (2 months); for each sample the z-average and PDI were measured in triplicate.
Table 1. Physicochemical Properties, Production Yield, and Assembly Eﬃciency of S/O BSA/HANanodispersions Prepared with
Diﬀerent Molecular Weight Hyaluronic Acid (Mean ± SD, n = 3)
samples BSA (mg/mL) HA Mw (kDa) HA (mg/mL) size av (nm) PDI PY (%) AE (%)
BSA-FITC 1 163.0 ± 5.0 0.247 ± 0.006 81.6 ± 0.015
A 0.1 800 0.006 237.7 ± 14.2 0.266 ± 0.04 70.9 ± 0.001 90.6 ± 0.028
B 0.5 50 0.006 115.5 ± 1.1 0.221 ± 0.02 75.5 ± 0.153 89.8 ± 0.042
C 0.5 15 0.006 160.9 ± 1.7 0.256 ± 0.005 70.8 ± 0.144 89.6 ± 0.008
D 0.5 20 ≤ Mw ≤ 50 0.006 129.7 ± 24.9 0.247 ± 0.04 77.2 ± 0.079 90.8 ± 0.095
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with a lipophilic surfactant (SE). This complex was then
dispersed in oil to obtain the ﬁnal S/O BSA/HA nanodispersion
(Figure 1).
Recently, we have demonstrated that one sucrose ester, the
surfactant SP10-C, has the potential to form stable complexes
with BSA.26 The ability of this surfactant to produce small and
Figure 4. Illustration of S/O nanodispersion of BSA/HA: (A) physical appearance, (B) size distribution obtained by PCS (photon correlation
spectroscopy), and (C) TEM microphotographs at magnitude 50000×.
Figure 5. (a) BJ-5ta and (b) NCTC2544 relative cell viability at 24 and 48 h of culture for S/O nanodispersion of BSA (0.5 mg/mL) mixed with HA
(0.006 mg/mL) at diﬀerent dilutions (% v/v formulation). Values for tested samples are presented in relation to the control (cells cultured with culture
medium scored 100% of viability). Results show the mean values of two replicates from four experiments carried out independently. Grouping
information using Tukey test with 95% of conﬁdence: means that do not share a letter are signiﬁcantly diﬀerent.
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stable nanodispersions in oil was a good starting point for
investigating the best ratio among SE:BSA:HA for the
production of nanodispersions containing hyaluronic acid. In
order to achieve the optimal molar ration between all the
components of the system, we mixed BSA-FITC (66 kDa) with a
wide range of molecular weight HA (800, 100 ≤ Mw ≤ 300, 50,
20 ≤ Mw ≤ 50, and 15 kDa).
The z-average diameter and PDI of S/O nanodispersions were
measured shortly after preparation (Figure 2). The size variations
demonstrated that the nanodispersed particle sizes closely
correlated to the SE:BSA:HA molar ratio. The molar ratio
between SE:BSA corresponding to 25mg/mLof SE and 0.5mg/mL
of BSA led to the smallest nanodispersions, particularly for 15,
50, and 20 ≤ Mw ≤ 50 kDa HA (160, 115, and 129 nm,
respectively). The best BSA:HA ratio obtained was 60:1
corresponding to 0.5 mg/mL of BSA with 0.006 mg/mL of
HA which imparted a pronounced particle size reduction. The
amount of BSA doubled compared to that without the presence
of HA.
3.1.1. S/O Nanodispersion Stability Studies. The monitoring
of S/O nanodispersion production involves the study of their
physical and biological stability. In order to evaluate physical
stability of S/O nanodispersions their size distribution and
polydispersity (PDI) was monitored immediately after produc-
tion and for three months of storage at room temperature. The
results shown in Figure 3 illustrate the combined simultaneous
measurements of average diameter and PDI for the best
nanodispersions for each HA tested. It seems clear that, after 2
months of storage, sample D displayed the lowest variation in terms
of particle size, as well as of polydispersity. Other nanodispersions,
especially B and C, are not so stable during storage, as illustrated by
the considerable vatiation in particle size (Figure 3). Sample D was
the chosen nanoformulation for further experiments.
The biological stability of formulation D was measured in
terms of lipid peroxidation during three weeks. As expected, no
oxidation was veriﬁed at time zero and a low oxidation level was
detected after one week (3.3 mmol/mL) and after three weeks
of storage (5.4 mmol/mL of MDA), corresponding to a
peroxidation level of 5.5%. These results suggest that no
additional antioxidant is required to prevent the production of
free radicals. The nanodispersion itself does not contribute to the
formation of oxidation products.
3.1.2. Production Yield and Assembly Eﬃciency of Nano-
dispersions. The production yield (PY) and the assembly
eﬃciency (AE) of S/O nanodispersions were evaluated. Table 1
presents the particle size, polydispersity, production yield, and
assembly eﬃciency for the formulations containing the diﬀerent
molecular weight HA. The assembly eﬃciency obtained was
higher than 89.6%, suggesting that almost all of the HA used in
the preparation of S/O nanodispersion was actually entrapped/
adsorbed by the protein. The production yield was greater than
70.5%.
The small size, low PDI, good stability, attractive price, and
desirable performance adds value to nanodispersion D as a
potential transdermal pharmaceutical−cosmetic product. Figure 4
illustrates spherical and homogeneous oil-based nanodispersion
with z-average diameter of around 130 nm conﬁrmed by TEM
results.
3.2. Cytotoxicity Evaluation. The cytotoxicity of the most
suitable nanodispersion produced was assessed in in vitro
cultured ﬁbroblasts and keratinocytes. In order to establish the
eﬀect of BSA mixed with HA nanodispersions on exposed BJ5ta
and NCTC2544 cells (Figure 5), all tested conditions were
evaluated after 24 and 48 h. No toxicity was observed for the
range from 0.5 to 2% v/v formulation, corresponding to the
concentrations of.2.5−10 μg/mL for BSA and 0.03−0.12 μg/mL
for HA, thought keratinocytes were slightly more sensitive to the
formulation.
3.3. In Vitro Permeation Studies of S/O Nanodispersion
To Achieve the Ideal Formulation Concentration.
Considering the previous best formulation (D) in terms of
particle size and stability and its low toxicity for concentrations in
the range of 2.5−10 μg/mL for BSA and 0.03−0.12 μg/mL of
HA, skin permeation studies were conducted. Quantitative
estimation for the permeation approaches of BSA/HA nano-
dispersions were performed and are presented in Figure 6. It is
Figure 6. Permeation proﬁle of S/O BSA/HA nanodispersions across abdominal pig skin. Formulations (a) 0.5% (v/v) corresponds to 2.5 μg/mL of
BSA and 0.03 μg/mL of HA; (b)1% (v/v) corresponds to 5 μg/mL of BSA and 0.06 μg/mL of HA and c) 2% (v/v) corresponds to 10 μg/mL of BSA
and 0.12 μg/mL of HA. Each point represent the mean± SD, n = 3. The data are expressed as the cumulative nanodispersion permeation (Qt) per unit
of skin surface area, Qt/A (A = 0.785 cm2).
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clear from the graph that the cumulative amount of BSA/HA
nanodispersion in the three concentrations exhibits an excellent
performance over time, mainly from 6 to 72 h. High cumulative
amounts were achieved like in other successful studies that
promote transdermal delivery of compounds through the
skin.38−40 Sample with 2% (v/v) presents the highest cumulative
amount of permeated BSA/HA conjugate corresponding to
greater skin diﬀusion. These results clearly demonstrate that the
penetration of HA into the skin is mainly due to its lipophilic
character, and an increase of the donor sample concentration,
strengthening percutaneous permeation eﬃciency.
TEM images in donor (initial nanodispersion) and in receptor
(ﬁnal nanodispersion solution) compartments showed irregular
nanodispersions of spherical integral small particles and
disintegrated larger particles. Several factors including test
duration, sampling frequency, sink condition, stirring rate,
diﬀusion membrane material, and others may contribute to
these irregularities and to the diﬀerences in the cumulative amount
values. Furthermore, the initial solution was composed of large
sized particles (Figure 7: a1, b3, and c5) that had a tendency to
aggregate and disintegrate when forced to diﬀuse by gravity.
The percutaneous penetration mechanism was also qualita-
tively analyzed by histological examination of the skin.
Fluorescent and confocal images of S/O BSA/HA nanodispersions
are shown in Figures 8 and 9. Comparing both control sample and
the corresponding ﬂuorescence images of the formulations,
ﬂuorescence emitted by FITC and RITC provides clear evidence
of percutaneous permeation and the successful permeation across
the SC layer and deeper diﬀusion into the dermis.
The permeation proﬁle of the BSA/HA nanodispersions
through the layers of pig skin were investigated by confocal laser
scanning microscopy. Confocal images in Figure 9 are divided
into 2D images (FITC, RITC, and Merge) and 3D, the upper
images (3D and a 3D close-up) showing penetration of BSA/HA
through the pig skin. Penetration through stratum corneum is the
rate limiting step in the overall transdermal delivery. Once the
formulation crosses stratum corneum, its further penetration or
absorption is relatively easy.41 Figures 9 clearly shows the
penetration of the formulation through the diﬀerent skin layers.
The hydrophobic moiety of formulation successfully allowed the
permeation of a hydrophilic compound (HA) through the
mortar and brick structure of stratum corneum, naturally
composed of corneocytes surrounded by lipid bilayers, resistant
to hydrophilic molecules. Confocal images corroborate the
previous assumption of formulation disintegration as it crosses
the skin. It is possible to observe, especially in the dermis layer,
high ﬂuorescence of the dissociated compounds.
4. DISCUSSION
HA has been extensively explored as a drug carrier for target
speciﬁc and long-acting delivery of protein, peptide, and
Figure 7. TEM microphotograph of BSA/HA nanodispersion of (a)
0.5% v/v formulation, (b) 1% v/v formulation, and (c) 2% v/v
formulation, in liquid donor compartment (1, 3, 5) and in liquid
receptor compartment (2, 4, 6), after 72 h of incubation at 37 °C.
Figure 8. Fluorescent images showing the penetration of BSA nanodispersion with HA into pig skin. Penetration of S/O BSA/HA nanodispersion at (a)
0.5%, (b) 1%, and (c) 2% v/v formulation. Thumbnails 1, 2, 3, and 4 (numbered left to right in each row) show the penetration of BSA-FITC at phase
contrast with ﬁlter FITC, HA-RITC at phase contrast with ﬁlter RITC, BSA-FITC with ﬁlter FITC, and HA-RITC with ﬁlter RITC, respectively.
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nucleotide therapeutics.13 Although there is no study available
using HA as nanodispersion for transdermal transport system,
this constitutes a surplus value for the pharmaceutical/cosmetic
area. HA is a powerful antioxidant, helping natural defenses and
keeping the skin youthful, hydrated, and toned. In previous work
we successfully demonstrated the possibility of delivering large
proteins (BSA) transdermally for a range ofmedical applications.26
Herein, we incorporated HA into the BSA nanodispersion and the
results demonstrated that the presence of HAdoes not unsettle the
ﬁnal nanodispersion. In addition, with the presence of HA a lesser
amount of protein is required which contributes for a lower
z-average diameter of the ﬁnal particle. The association of BSA
with HA was crucial because its presence prevented the emulsion
instability (data not shown). A similar addition was used by Piao
et al. to prevent the release of sodium diclofenac into the S/O
suspension.42 The formulation optimization was conducted by
study of a wide range of HA molecular weights at diﬀerent
conditions. An optimum molar ratio among SE:BSA:HA in the
Figure 9. Confocal images of BSA/HA nanodispersions in epidermis and dermis pig skin. Bottom illustrations: FITC images correspond to the green
color with emissionmaxima at 520 nm emitting from FITC labeled BSA protein, and RITC correspond to the red color with emissionmaxima at 595 nm
emitting from RITC labeled HA. The Merge images (FITC + RITC) combine green and red ﬂuorescent signals emitted from the same sample. Upper:
3D illustration combines green and red channels (FITC-BSA green and RITC-HA red channel), and the yellowish color symbolizes the overlapping of
both. The right 3D (close-up) image demonstrates the view of the skin piece in detail where the penetration of FITC-BSA and HA-RICT is easily
detected.
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complex was found. The results demonstrated that nano-
dispersions from lower molecular weight HA displayed the smaller
particle sizes. This ismainly due to the lowmolecular weight of HA
allowing small extent of polymerization and gives rise to short
carbohydrate chains of small molecular size, which render high
chain ﬂexibility to assemble, small three-dimensional structures,
and weak steric interference, favoring the formation of a compact
assembly of BSA/HA.14 The collective results revealed that
nanodispersions were stable over threemonths in terms of physical
and chemical stability. These results were expectable because BSA/
HA molecules were coated with hydrophobic surfactant, which
leads to stronger hydrophobicity enhancing their dispersion into
the oil phase and boosting compactness of the ﬁnal S/O BSA/HA
nanodispersion. Moreover, it was reported that a typical S/O
nanodispersion can be prepared with low viscosity of the system
resulting from the low surfactant concentration.25 The stability of
S/O nanodispersion is suﬃciently high to prevent precipitation or
particle size changes for up to one month.43
Reinforcing the good results obtained in terms of particle size,
stability, and attractive price, the developed S/O BSA/HA nano-
dispersion does not present toxicity in the range of 2.5−10 μg/mL
for BSA and 0.03−0.12 μg/mL of HA. The concentration range
selected constitutes the composition for designing a BSA/HA
formulation as potential transdermal delivery for biopharmaceut-
ical demands. In these conditions, S/O BSA/HA nanodispersions
are able to reach the lipid skin layers and the presence of HA can be
detected in the deeper layers of the skin.
The successful permeation through the skin was evaluated by
quantitative and qualitative estimation. The results suggest that
BSA/HA nanodispersion disintegrates as it crosses the stratum
corneum into the dermis. HA has a lowmolecular weight and was
60× (molar ratio BSA/HA 60:1) less concentrated compara-
tively with BSA, making it more eﬀective to diﬀuse deeper into
the skin layer. Thus, as the S/O BSA/HA nanodispersion
permeates the skin and the BSA could be hydrolyzed by
proteases residing in the medium, the HA became more available
and deeply diﬀuse into the skin. These factors would increase its
availability, accessibility, and activity to act on the desired skin
targets.
5. CONCLUSIONS
BSA/HA S/O nanodispersion production was successfully
achieved by a two phase high energy methodology. The
quantitative and qualitative in vitro permeation results success-
fully demonstrated the eﬀective penetration of BSA/HA
nanodispersion to the epidermis and even to the dermis of pig
skin. These results reveal the feasibility of using S/O nano-
dispersions of BSA/HA as a model system for the improvement
of skin biomechanical properties and maintenance of an optimal
hydration level and ﬁrmness. Moreover, transdermal hyaluronic
acid could be a stimulating way to replenish HA in the dermis
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